BIOLOGICAL AND CLINICAL SIGNIFICANCE OF SERUM SURFACTANT PROTEINS SP-A AND SP-D IN NON-SPECIFIC INTERSTITIAL PNEUMONIA
Keywords:
interstitial lung disease, nonspecific interstitial pneumonia, epidemiology, age, clinical features, predictors, surfactant proteins.Abstract
Interstitial lung diseases (ILD) account for 10-15% of all lung diseases. According to the Agency on Statistics in Uzbekistan, in January-September 2024, a total of 131.7 thousand people died in the country, 6.5% of which were due to respiratory diseases. The clinical and epidemiological characteristics of patients with NSIP, as well as the role of surfactant proteins, remain not fully understood. The aim of the study: to study the prognostic prospects for determining serum surfactant proteins SP-A and SP-D in non-specific interstitial pneumonia (NSIP) in the Samarkand region for the period from 2020 to 2024. Materials and methods: We analyzed medical records of 262 patients with interstitial lung disease who were hospitalized at the Samarkand State Medical University. Taking into account the criteria of the international classification of diseases (ICD-10), patients diagnosed with NSIP and a comparison group, patients with COVID-19AP, were identified. Results: Total number of patients 262. The first group - patients with NSIP 190 (72.5%) The second - patients with COVID-19AP 72 (27.5%) and a control group of 20 patients. The study included patients in the age category from 18 to 90 years. Immunological research methods (ELISA method), the DR 191139200R Human Surfactant Protein A ELISA kit is designed to quantitatively determine the human surfactant A protein. The DR 194059100 Human Surfactant Protein D (SP-D) ELISA kit is designed to quantitatively determine human surfactant protein D (SP-D). Conclusion: Based on the data available today, we can confidently speak about the important, one of the key roles of SP-A and SP-D in the pathogenesis of NSIP, the development of life-threatening conditions.
References
Авдеев С.Н., Чикина С.Ю., Тюрин И.Е., Белевский А.С., Терпигорев С.А., Ананьева Л.П., Визель А.А., Болдина М.В., Демко И.В., Лещенко И.В., Трофименко И.Н., Киняйкин М.Ф., Степанян И.Э., Зайцева А.С., Петров Д.В. Хронические фиброзирующие интерстициальные заболевания легких с прогрессирующим фиброзным фенотипом: резолюция Междисциплинарного Совета экспертов. Пульмонология. 2021; 31 (4): 505–510. DOI: 10.18093/0869-0189-2021-31-4-505-510
Вершинина М.В. Идиопатические интерстициальные пневмонии.//Лечащий врач. 2013. № 1. С. 3 - 9.
Илькович М.М. Интерстициальные заболевания легких: рассуждения на актуальную тему. Часть 1. Consilium Medicum. Болезни органов дыхания. (Прил.) 2014; 01: 4-7.
Илькович М.М. Интерстициальные заболевания легких: рассуждения на актуальную тему. Часть 2. Consilium Medicum. Болезни органов дыхания. (Прил.) 2014; 01: 7-9.
Пульмонология. Национальное руководство. М.: ГЭОТАР-Медиа, 2009. - 960 с.
Респираторная медицина. Руководство (в 2-х томах М. ГЭОТАР- Медиа. 2007.С757.
Розенберг О.А. Легочный сурфактант и его применение при заболеваниях легких. Общая реаниматология. - 2007. - №1. - С. 66-77.
Синюкова Т.А., Коваленко Л.В. Сурфактантные белки и их роль в функционировании дыхательной системы. Вестник СурГУ Медицина. - 2011. - №9. - С. 48-54.
Цветкова О.А., Воронкова О.О., Буянова О.Е. Современный подход к терапии больных идиопатическим легочным фиброзом. Клиническая медицина.2017. №3. С.281 - 285.
Teoh AKY, Corte TJ. Nonspecific Interstitial Pneumonia. Semin Respir Crit Care Med. 2020 Apr; 41(2):184-201.doi: 10.1055/s-0040-1708499. Epub 2020 Apr 12. PMID: 32279290.
Belloli EA, Beckford R, Hadley R, Flaherty KR. Idiopathic non-specific interstitial pneumonia. Respirology. 2016 Feb;21(2):259-68. doi: 10.1111/resp.12674. Epub 2015 Nov 13. PMID: 26564810.
Wells AU, Cottin V. Nonspecific interstitial pneumonia: time to be more specific? Curr Opin Pulm Med. 2016 Sep;22(5):450-5. doi: 10.1097/MCP.0000000000000302. PMID: 27428647.
Tomassetti S, Ryu JH, Piciucchi S, Chilosi M, Poletti V. Nonspecific Interstitial Pneumonia: What Is the Optimal Approach to Management? Semin Respir Crit Care Med. 2016 Jun; 37(3):378-94.doi: 10.1055/s-0036-1583176. Epub 2016 May 27. PMID: 27231862.
van den Bosch L, Luppi F, Ferrara G, Mura M. Immunomodulatory treatment of interstitial lung disease. Ther Adv Respir Dis. 2022 Jan-Dec;16:17534666221117002. doi: 10.1177/17534666221117002. PMID: 35938712; PMCID: PMC9364223.
Samarelli AV, Tonelli R, Marchioni A, Bruzzi G, Gozzi F, Andrisani D, Castaniere I, Manicardi L, Moretti A, Tabbì L, Cerri S, Beghè B, Dominici M, Clini E. Fibrotic Idiopathic Interstitial Lung Disease: The Molecular and Cellular Key Players. Int J Mol Sci. 2021 Aug 19;22(16):8952. doi: 10.3390/ijms22168952. PMID: 34445658; PMCID: PMC8396471.
Li XR, Peng SC, Wei LQ. Nonspecific interstitial pneumonia overlaps organizing pneumonia in lung-dominant connective tissue disease. Int J Clin Exp Pathol. 2015 Sep 1;8(9):11230-5. PMID: 26617847; PMCID: PMC4637662.
Spadaro S, Park M, Turrini C, et al. Biomarkers for Acute Respiratory Distress syndrome and prospects for personalised medicine. J Inflamm. 2019;16(1). doi: 10.1186/s12950-018-0202-y
El-Deek SE, Makhlouf HA, Saleem TH, et al. Surfactant protein D, soluble intercellular adhesion molecule-1 and high-sensitivity C-reactive protein as biomarkers of chronic obstructive pulmonary disease. Med Princ Pract. 2013;22:469-74. doi: 10.1159/0003499
